DelveInsight’s Trending Reports 2022: Chondrosarcoma Market, Microsatellite Stable Colorectal Cancer Market, Rituximab Biosimilars Insight, Pain Management Devices Market, 22q11.2 Deletion Syndrome Market.
Chondrosarcoma Market Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by syndrome. Some of the facts: · According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer. · Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20. · Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance. · Chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. Malignant transformation occurs in 5% of osteochondromas, either multiple or solitary forms. Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market Some of the Chondrosarcoma Companies · Agios Pharmaceuticals · Forma Therapeutics · Eli Lilly and Company · PharmaMar · And Many Others Chondrosarcoma Drugs Covered: · AG-120 · Olutasidenib · LY3410738 · Trabectedin · And Many Others Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market Microsatellite Stable Colorectal Cancer Market Microsatellite stable colorectal cancer bears fewer signals that alert the immune system to cancer. So checkpoint inhibitors, such as nivolumab, have been unsuccessful in treating MSS colorectal cancer (CRC). Clinical trials have been going on to develop the promising drug for MSS colorectal cancer. Some facts of Microsatellite Stable Colorectal Cancer Market Report are: · Approximately 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2. · According to DelveInsight, Microsatellite Stable Colorectal Cancer Market is expected to grow at CAGR of XX% during the forecast period. · Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux are recent additions to the Metastatic Colorectal Cancer treatment market. · Talking about gender-predisposition, CRC is the third most commonly diagnosed cancer in males and the second in females. It is most frequently diagnosed in people of age group 65–74. Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market Some of Microsatellite Stable Colorectal Cancer Companies in the market: Gritstone Oncology Merck Sharp & Dohme Corp. Arrys Therapeutics NeoImmuneTech And Others Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market Microsatellite Stable Colorectal Cancer Drugs GRANITE MK7123-034 NT-I7 TPST-149 And Many Others Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market Rituximab Biosimilars Insight Rituximab is a type of antibody therapy, which can be used alone or with chemotherapy. They work in different ways to catch and attack the cells where cancer occurs. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used for treating certain types of cancer. It works by reducing or prohibiting the growth of cancer cells. This drug is also used for treatment of certain types of blood vessel disease, decrease the swelling of the blood vessels, and treat a specific skin condition. Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight Rituximab Biosimilars Drugs covered in the report:- IBI-301 RGB 03 RITUMAX ABP 798 AcellBia/Usmal Blitzima/Truxima BX 2336 DRL_RI GP2013 HLX01 iBio Rituximab IBPB 001RX MK-8808 Ritemvia/Blitzima Riximyo RTXM83 Ruxience AP 052 Retuxira TL-011 RituxiRel Kikuzubam LBRx DRL-rituximab MG1106 GB-241 Rilast HS 006 BX 2336 GNR-006 Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight Scope of Rituximab Biosimilars report Major Players in Rituximab – 35+ key companies Phases – 35+ products under different phases of clinical development Marketed stage products Late-stage products (BLA Filed and Phase III) Mid-stage products (Phase II) Early-stage products (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Route of Administration Subcutaneous Intravenous Molecule Type Molecule types Monoclonal antibodies Peptide Protein Small molecule Product Type Product Types Mono Combination Mono/Combination Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight Pain Management Devices Market Pain management is a field of medical science that makes it easier for people with chronic pain who suffer. Acute pain has a rapid onset of action, while chronic pain lasts for a prolonged period of time, causing it to to be managed. Pain management device is a medical system used to treat various forms of pain, such as neuropathic pain, cancer pain, nociceptive pain, musculoskeletal pain, and others. Some key facts of the Pain Management Devices Market · Global Pain Management Devices Market is expected to grow at a CAGR of 7.89% during the forecast period from 2021 to 2026. · The demand for Pain Management Devices is primarily motivated by the rise in prevalence of chronic pain, high prevalence of musculoskeletal disorders, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and increasing cost of healthcare expenditure. · According to World Health Organization (2019), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. View Report: https://www.delveinsight.com/report-store/pain-management-devices-market Some of the Pain Management Devices Companies are: · St. Jude Medical, Inc. · Boston Scientific Corporation · Medtronic plc · Smiths Medical · Abbott · Nevro Corp. · Stimwave LLC · And Many More Pain Management Devices Market Drivers · Growing need for long-term pain relief in the geriatric consumer · Large & rising population base of patients · Adverse effects of pain medications · Widely demonstrated effectiveness of pain management devices View Report: https://www.delveinsight.com/report-store/pain-management-devices-market 22q11.2 Deletion Syndrome Market 22q11.2 Deletion Syndrome is a condition that develops because of chromosome defects and is a complex, multi-organ disorder noted for its varying severity and penetrance among those affected. As per several studies, it is the most common chromosomal microdeletion reported in humans. Some facts of 22q11.2 Deletion Syndrome Market are: In 2020, the total prevalent cases of 22q11.2 deletion syndrome were 196,476 in the 7MM. The United States, in the same year, accounted for 83,326 cases, the highest prevalence of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020. Among the EU-5 countries, the highest number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain in 2020. 22q11.2 deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. In the EU-5 countries, the total diagnosed prevalent cases of 22q11.2 deletion syndrome were 35,203 in 2020. · 22q11.2 deletion syndrome is a multisystem disorder characterized by several physical, behavioral and psychiatric disorders. In the 7MM, of the focused age-group 6 to 12 and 13 to 17 years, the diagnosed prevalent cases of 22q11.2 deletion syndrome with Behavioral and Psychiatric Phenotypes were 36,702, in 2020. View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market Some of 22q11.2 Deletion Syndrome Companies are: · Zynerba Pharmaceuticals · Enzyvant · Roivant Sciences · Sumitomo Dainippon Pharma · And Many Others Some of 22q11.2 Deletion Syndrome Therapies are: · Zygel (ZYN002) · RVT-802 · And Many Others View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach. Some of Newly Launched Report: Acute Lung Injury Market Adamantinoma Market Defibrillators Market Urolithiasis Market Cardiac Resynchronization Therapy Device Market Aesthetic Implants Market Alzheimer Disease Market Central Venous Catheters Market Biochips Market Alopecia Market Cardiac Monitoring Devices Market Biliary Tumor Market Foot And Ankle Devices Market Hyperuricemia Market Invasive Candidiasis Market Global Electrophysiology Devices Market Neurovascular Devices Market Blood Glucose Monitoring Systems Market Neurostimulation Devices Market Human Papilomavirus Market Capnography Device Market Ventilator Market Breast Pumps Market Metastatic Bone Pain Market Brain Aneurysm Stents Market Atypical Hemolytic Uremic Syndrome Ahus Market 2 Deletion Syndrome Market X Linked Hypophosphatemia Market Parkinsons Disease Related Dementia Market Ocular Motility Disturbance Market Palmar Hyperhidrosis Market Size Pulse Oximeters Market Diagnostic Imaging Equipment Market Continuous Renal Replacement Therapy Machines Market Pain Management Devices Market Glycogen Storage Disease Market Rituximab Biosimilars Insight Epithelial Ovarian Cancer Market Cardiac Biomarkers Testing Devices Market Chronic Myelogenous Leukemia Market Bone Grafts And Substitutes Market Idiopathic Membranous Nephropathy Market Advanced Renal Cell Carcinoma Market Sialidosis Market Prosthetic Joint Infection Market Microsatellite Stable Colorectal Cancer Market Higher-Risk Chronic Myelomonocytic Leukemia Market Chondrosarcoma Market Car T Therapy For Acute Lymphoblastic Leukemia All Market Related Blogs: Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment Mapping the Biggest Pharmaceutical Companies by Continents Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers Major Drugs Decisions for Cardiovascular Diseases to Watch Through 2022 Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021 Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market Cybersecurity in Healthcare: Major Threats and Challenges Top Drugs To Watch in HIV (2025) About Delveinsight: DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems. Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: email@example.com Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com Connect With Us at: LinkedIn | Facebook | Twitter